Replies to post #46448 on Premier Biomedical Inc (BIEI)

[fishreplicas1]

The conversation was cancer...period... not specific... your the one who made it specifically about one little sliver of the company's research.

- the last I checked a patent on a form of chemo treatment was pretty cool accomplishment in THE CANCER RESEARCH FIELD !

We all know what's up... and we all know the exact point when some people buy back in...

Best of luck to the honest ones here!

[fishreplicas1]

Like this one -Extracorporeal Treatment of Bodily Fluids
U.S. Patent No. 9,216,386

Issued December 22, 2015

Abstract.

An article and method to treat extracorporeally a patient’s bodily fluid. The bodily fluid can include blood, cerebral spinal fluid and lymph. A first stage of the method includes applying a treatment, The treatment can comprise dosing with a medication, thermal treatment, or irradiation. The treatment can occur at levels that could otherwise compromise the patient’s health, A second stage of the method substantially removes the treatment from the bodily fluid. The bodily fluid can then be returned to the patient. The article includes a treatment chamber that applies the treatment and a removal module for removing the treatment. The method can be a continuous process such as, for example, a dialysis process.

View the full patent here.

[squidster]

To your credit, you obviously know the U.S. patent system better than most and I have appreciated your insight regarding that. It would seem that your investment thesis is based around the CTLA-4 patent, that's cool but I would suggest that there are other facets to the biolgics division that could bring in outside interest as well. So it's not so obvious to me that there is no interest outside of the patent. So let's just agree to disagree...
In the meantime the pain management division seems to be gaining traction and if there is enough revenue there to keep from further dilution I am willing to sit tight for awhile longer